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Purpose: To analyze the effect of allogeneic blood transfu-
sion on clinical outcome in 119 patients with stage IIB cervical
cancer who were treated with radiotherapy ± chemotherapy.
Patients and Methods: Medical records were examined for
hemoglobin levels before and during radiotherapy, history of
allogeneic blood transfusions and the time point when
transfusions were given. These factors were retrospectively
analyzed along with other clinical risk factors for influences
on the patients’ clinical outcomes. Results: Thirty-two patients
(26.9%) received packed red blood cell transfusion (mean, 3.4
units; range, 1-12 units) before or during radiotherapy. Median
follow-up period was 39.3 months (range, 7.6 - 58.4 months).
Patients with history of transfusion showed poorer metastasis-
free survival and a trend toward poorer overall survival than
non-transfused patients. When patients who received transfu-
sions were sub-divided by the time of transfusion, those who
received transfusions before radiotherapy had significantly
poorer clinical outcome than those who received transfusions
during radiotherapy. In a multivariable analysis, patients with
pretreatment transfusion showed a higher risk of distant
metastasis (HR = 3.75, 95% CI: 1.28 - 12.15, p = 0.017) and
decreased overall survival rates (HR=4.62, 95% CI: 1.15-18.54,
p = 0.031) compared with those of other patients. Conclusion:
Our results suggest that allogeneic blood transfusions given
before radiotherapy may be associated with higher incidence
of distant metastases and decreased survival in patients with
stage IIB cervical cancer.
Key Words: Anemia, blood transfusion, cervical cancer,
metastasis, radiotherapy
INTRODUCTION
One of the most commonly encountered medical
conditions among cancer patients is anemia, which
is frequently caused by tumor bleeding, malnu-
trition, and other tumor-associated metabolic pro-
cesses, as well as the myelosuppressive effects of
various anticancer agents. In women with cervical
cancer, blood loss due to acute or chronic vaginal
bleeding is the most frequent cause of anemia.
Incidence of anemia at the time of diagnosis
(hemoglobin level < 12 g/dL) is 25 - 40%, and this
incidence is higher in more advanced stage
diseases.
1,2 It was shown by Vaupel et al. that the
median pO2 in cervical and vulvar cancers
increases significantly at a mean hemoglobin (Hb)
of 13 ± 0.1 g/dL, and decreases toward either side
of the value, suggesting that an optimal Hb level
for maximal oxygen saturation in the tumor tissues
is around 13 g/dL.
3 Patients with low Hb have
been treated with allogeneic blood transfusions
(ABT) before radiotherapy because anemia was
thought to have adverse effects on treatment out-
come by aggravating tumor hypoxia and resistance
to radiotherapy. This belief was supported by the
findings from the largest retrospective review of
over 600 patients treated at 7 different cancer
centers in Canada which showed Hb below 12 g/
dL was associated with bad prognosis after radio-
therapy.
4-6 More recently, anemia has been reported
to cause chronic fatigue in patients with cancer,
and the importance of preventing and treating
anemia has been emphasized in the context of
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improving the quality of life of cancer patients.
7
Use of human recombinant erythropoietin com-
pounds has been suggested as a solution, es-
pecially to prevent treatment-related anemia,
however, administration of these agents to patients
with cervical cancer is a topic of debate due to the
reports of an association of these compounds with
unfavorable treatment outcomes.
8,9 In addition,
these agents do not rectify anemia as rapidly as
blood transfusions, and hence, blood transfusions
are still needed in patients who have insufficient
physiologic compensatory mechanisms for low
hemoglobic level and tissue hypoxia.
10-12 On the
other hand, ABT is associated with the develop-
ment of transfusion-related immunomodulation
and the role of ABT has been challenged, because
of several reports showing poor oncologic out-
comes in patients who received blood transfu-
sions.
13-17 In the background of these conflicting
aspects of ABT in the management of anemia, we
retrospectively analyzed the effect of ABT on
clinical outcomes in patients with FIGO stage IIB
uterine cervical cancer.
PATIENTS AND METHODS
Patients and treatment
The patient population consisted of 119 women
with FIGO stage IIb cervical cancer who were
treated with radiotherapy between July 2001 and
March 2005. One hundred seven of these women
(90%) also received weekly cisplatin, whereas 12
patients (10%) were treated with radiotherapy
alone. Radiotherapy consisted of 45 - 50 Gy ex-
ternal beam radiotherapy in 1.8 Gy fractions with
high-dose-rate brachytherapy beginning during
week 4 - 5 of external beam radiotherapy. Point A
was irradiated up to total 85 - 90 Gy and intraven-
ous cisplatin (40 mg/m
2 body surface area) was
administered once weekly during radiotherapy.
All patients completed treatment within 42 to 79
days (median, 52 days).
Anemia and allogeneic blood transfusion
It has been our treatment policy to maintain
patient Hb levels above 10 g/dL before or during
radiotherapy, and transfusion of packed RBC was
recommended for patients with Hb less than 10g/
dL at any given time before or during radiotherapy.
This resulted in 32 cases of transfusions, among
which 15 cases received pre-treatment transfusion.
Filters were not used for transfusion on a routine
basis, and leukocyte-depleted blood component
was not used in any patient during this period in
our clinic. To evaluate the effect of anemia and
transfusion, we examined the effect of 2 different
values of Hb; i.e., baseline Hb (BHb) and average
weekly nadir Hb (AWNHb). BHb represents the
lowest Hb value before radiotherapy, whereas
weekly nadir Hb (WNHb) was the lowest Hb value
during each week of radiotherapy, with AWNHb
being the average of WNHbs. The effects of ABT
were compared in patients who did or did not
receive transfusions, as well as whether transfu-
sions were given before radiotherapy began or
during radiotherapy. We further examined
whether patients with Hb less than 10 g/dL had
microcytic or normocytic anemia by looking at the
mean corpuscular volume (MCV) and red blood
cell distribution width (RDW). Microcytic anemia
was defined as MCV less than 80 fL. According
to the recent review of diagnosis of anemia,
18 iron
deficiency anemia (IDA) is microcytic anemia
which is mostly associated with increased RDW.
If normocytic or macrocytic, the presence of
elevated serum ferritin level favors diagnosis of
anemia of chronic disease (ACD), especially when
associated with normal RDW (reference of RDW,
11.5 - 14.5%).
Statistical analysis
Distribution of the patients' characteristics was
presented by median (range) or mean (SD) for
continuous variables, and frequency (%) for cate-
gorical variables including tumor size, histology
type, pelvic lymph node status, laparoscopic
lymph node staging (LLND), BHb, and AWNHb;
transfusion vs. non-transfusion; pretreatment
transfusion (PTf) vs. transfusion only during treat-
ment (DTf) vs. non-transfusion group. Student's
t-test was performed to test for distribution dif-
ferences in BHb and AWNHb values for various
clinical parameters. Locoregional recurrence-free
survival (LRRFS), metastasis-free survival (MFS),Allogeneic Blood Transfusion Given Before Radiotherapy
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and overall survival (OS) were evaluated by the
Kaplan-Meier method and were tested using log-
rank test. To account for potential confounding
effects on survival outcomes, Cox proportional
hazards model was employed using the general
strategy for model selection involving the hierarchic
principle with the likelihood ratio chi-square test.
All reported p values were 2 sided and the results
were considered as significant at p < 0.05. All stati-
stical analyses were performed with SAS statistical
software (ver. 8.01, SAS Institute Inc., Cary, NC,
USA).
RESULTS
Patient characteristics
The median follow-up for survivors was 39.3
months (range, 7.6 - 58.4 months), and median age
of the patients was 60 years (range, 23 - 80 years).
Of the 119 patients, 105 (88%) had histologic dia-
gnosis of squamous cell carcinoma, with the
remainder having adenocarcinoma or adenosqua-
mous cell carcinoma. Median tumor diameter was
4.0 cm (range, 2.0 - 12.3 cm). Forty-five (38%)
patients had metastases to the pelvic LNs, as
shown by LLND or radiological imaging, inclu-
ding MRI and/or PET-CT. Patients found to have
nodal metastases outside the pelvis were excluded
from this study. Laparoscopic lymph node staging
was performed in 42 (35%) patients prior to
radiotherapy (Table 1).
Incidence of anemia and frequency of blood trans-
fusions
The median values for BHb and AWNHb were
12.0 g/dL (range, 6.0 - 14.7 g/dL) and 11.1 g/dL
(range, 9.0 - 13.4 g/dL), respectively. In our series,
the proportion of microcytic anemia in 18 patients
whose BHb was less than 10g/dL was 7 patients
with the rest of the patients having MCV over 80
fL (Table 2). Five of these patients had increased
RDW, suggesting iron deficiency anemia. For 11
patients who were normocytic, there were possi-
bilities that they had anemia due to chronic
disease, caused by cancer or other chronic sys-
Table 1. Patient Characteristics
Factors Patients (n) %
Age (yrs)
< 50 44 37
50 75 63
Tumor size (cm)
< 4 51 43
4 68 57
Pelvic LN metastasis
Positive 45 38
Negative 74 62
LLND
Yes 42 35
No 77 65
Chemotherapy
Yes 107 90
No 12 10
Histology
SCC 105 88
Non-SCC 14 12
BHb
< 10 g/dL 18 15
10 g/dL 101 85
AWNHb
< 10 g/dL 13 11
10 g/dL 106 89
PTf
No 104 87
Yes 15 13
DTf
No 102 86
Yes 17 14
Transfusion
No 87 73
Yes 32 27
AWNHb, average weekly nadir hemoglobin; BHb, baseline
hemoglobin; DTf, transfusion only during treatment; LN,
lymph node; LLND, laparoscopic lymph node dissection; PTf,
pretreatment transfusion; SCC, squamous cell carcinomaMyong Cheol Lim, et al.
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temic disease. In our patients, there was higher
incidence of normocytic anemia in older patients
(5/9 in < 50 vs. 3/4 in 50), suggesting the con-
tribution of chronic condition promoting cytokine-
mediated process, which leads to poor RBC pro-
duction or interference of erythropoietin produc-
tion in this age group. Overall, 32 patients (27%)
were given at least one transfusion before or
during radiotherapy, with 23 (23/32, 72%) recei-
ving a single transfusion and 9 (9/32, 28%) recei-
ving more than 1. Patients who were given
transfusion received an average of 3.4 units of
packed red blood cells (range, 1 - 12 units). Fifteen
patients (13%) received transfusions before treat-
ment and 17 (14%) only during treatment (Table
1). Fig. 1 shows the numbers of patients who
received ABT before and during the course of
radiotherapy and their Hb values. Average BHb
was 8.5 g/dL (n = 15) for patients who had PTf
and 11.8 g/dL (n = 104) for the remainder. This
difference in mean Hb levels decreased during the
course of radiotherapy, and the significance of
mean Hb differences was lost by the second week
after initiation of treatment (Fig. 1). When the Hb
variables were analyzed in relation to clinical
parameters, we found that BHb and AWNHb
below 10 g/dL were significantly associated with
younger age (p = 0.002 and 0.001, respectively,
Table 3). Patients who underwent LLND showed
a decrease in Hb levels after surgery, and the
AWNHbs remained lower through the entire
treatment period than in those who did not
undergo LLND (Fig. 2 and Table 3), although BHb
did not differ between the two groups. Overall,
patients who underwent LLND received more
frequent transfusions than the remainder of the
patients, before and during radiotherapy (27/42,
64.3% vs. 19/77, 24.7%, respectively). Fig. 3 shows
that the patients who were treated with weekly
cisplatin chemotherapy concurrently with to
radiotherapy had a significant decrease in Hb
levels after the fourth week of radiotherapy (p =
0.008, 0.015, and 0.009 for 4th, 5th, and 6th week
respectively).
Analysis of prognostic parameters and clinical
outcomes
Locoregional recurrence developed in 12 patients
(10%). Sites of recurrence included the cervix (n
= 5), pelvic LN (n = 6), and pelvic peritoneum (n
= 2). Distant metastases were observed in 14
Table 2. Type of Anemia
Patients
(n)
MCV < 80 fL MCV 80 fL
n % n %
BHb 18 7 38.9% 11 61.1%
Increased RDW 5 71.4%
AWNHb 13 5 38.5% 8 61.5%
Increased RDW 1 20.0%
AWNHb; average weekly nadir hemoglobin, BHb; baseline hemoglobin, MCV; mean corpuscular volume, RDW; red blood cell
distribution width.
Fig. 1. Average weekly nadir hemoglobin values in
patients who received blood transfusions before the
initiation of radiotherapy (open circles) and in patients
who did not receive transfusions (closed circles).
Transfusion frequency in patients with (white column) and
without (black column) pretreatment transfusions.Allogeneic Blood Transfusion Given Before Radiotherapy
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Table 3. Factors Influencing Hemoglobin Level
Factors
BHb AWNHb
Mean ± SE p value* Mean ± SE p value*
Age (yrs) 0.002 0.001
< 50
50
11.2 ± 0.27
12.2 ± 0.19
10.7 ± 0.13
11.3 ± 0.10
Tumor size (cm) 0.174 0.621
< 4
4
12.1 ± 0.21
11.6 ± 0.23
11.1 ± 0.12
11.1 ± 0.11
Pelvic LN metastasis 0.301 0.104
Negative
Positive
11.8 ± 0.26
11.8 ± 0.20
10.9 ± 0.13
11.2 ± 0.11
LLND 0.650 < 0.001
Yes
No
11.7 ± 0.27
11.9 ± 0.20
10.7 ± 0.12
11.3 ± 0.10
Chemotherapy 0.402 0.089
Yes
No
11.9 ± 0.17
11.4 ± 0.37
11.0 ± 0.09
11.5 ± 0.19
Histology 0.366 0.405
SCC
Non-SCC
11.9 ± 0.17
11.4 ± 0.45
11.1 ± 0.09
10.9 ± 0.21
AWNHb, average weekly nadir hemoglobin; BHb, baseline hemoglobin; LN, lymph node; LLND, laparoscopic lymph node
dissection; SCC, squamous cell carcinoma; SE, mean of standard error.
*Student’s t-test was performed to compare the differences in hemoglobin level by 2 groups.
Fig. 2. Effect of laparoscopic lymph node dissection on
anemia and transfusion. Closed circle and shaded column
represent patients with laparoscopic surgery (n = 42).
Open circle and white column represent patients without
laparoscopic surgery (n = 77). PreOp, Hemoglobin at initial
presentation; PreRT, Nadir hemoglobin at the time of
initiation of radiotherapy.
Fig. 3. Effect of chemotherapy on hemoglobin and transfu-
sion. Open circle and white column represent patients
undergoing chemotherapy (n = 107), whereas, closed circle
and black column for patients without chemotherapy (n =
12).Fig. 4. Overall survival rate according to
the age group, stratified by Baseline Hb
10g/dL. (A) Patients < 50 yrs, p = 0.36,
(B) Patients 50 yrs, p = 0.028, p value
calculated by log rank test. Solid line
BHb 10 g/dL, Broken line BHb < 10
g/dL
Myong Cheol Lim, et al.
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patients (12%), located in the para-aortic LN (n =
10), liver (n =1), lung (n =3), abdominal peritoneum
(n = 2), and supraclavicular LN (n = 1). Ten patients
had combined locoregional recurrence and distant
metastasis, with 4 of them having recurrent pelvic
and para-aortic lymphadenopathies.
Univariate analysis of clinical outcomes showed
that BHb was associated with significantly poorer
OS (p = 0.032). When the effect of BHb was further
analyzed by the patients’ age, BHb was significant
for overall survival in patient of age 50 years
(p = 0.028), but not for patients under 50 years (Fig.
4). Lower AWNHb level showed a tendency to be
associated with higher locoregional recurrence, but
this result did not reach a statistical significance
(p = 0.089). Age below 50 years, non-squamous
histology, the presence of metastatic pelvic LN and
lower AWNHb level were other significant factors
associated with the higher rate of locoregional
recurrences (Table 4). From multivariable analyses,
the presence of metastatic pelvic LN and non-
squamous histology remained as prognostic
factors for locoregional recurrence. Patients with a
history of transfusion showed a significantly
poorer metastasis-free survival than patients
without transfusion (4-years metastasis-free sur-
vival, 72% vs. 87%, p = 0.007, Fig. 5a) and about
5.7 fold higher risk of distant metastases (HR 5.70,
CI 1.26- 10.73, p = 0.017, data not shown), although
it did not reach statistical significance in terms
Fig. 5. (A) Metastasis-free survival in patients with transfusion vs. non-transfusion (4-year MFS rates 72% vs. 87%, p =
0.007, p value calculated by log rank test). (B) Metastasis-free survival in patients with no transfusion, with transfusion
only during treatment, or with transfusion before treatment (4-year MFS rates 87%, 78%, and 66%, respectively). (C)
Overall survival in patients with no transfusion, with transfusion only during treatment, or with transfusion before
treatment (4-year OS rates 88%, 92%, and 72%).
A B
A B CTable 4. Univariable Analysis of Clinical Outcome with Variables
Factors
Patients
(n)
LRRFS MFS OS
4-yr
LRRFS
p value*
4-yr
MFS
p value*
4-yr
OS
p value*
Age (yrs)
< 50 44 78 0.004 82 0.395 74 0.351
50 75 94 83 93
Tumor size (cm)
< 4 51 89 0.443 85 0.762 95 0.121
4 68 87 78 80
Histology
SCC 105 92 < 0.001 83 0.306 92 0.447
Non-SCC 14 62 76 68
Pelvic LN metastasis
Positive 45 79 0.009 83 0.276 83 0.216
Negative 74 93 80 86
LLND
Yes 42 93 0.420 90 0.492 92 0.747
No 77 85 79 83
BHb
< 10 g/dL 18 89 0.876 77 0.193 77 0.032
10 g/dL 101 88 83 87
AWNHb
< 10 g/dL 13 77 0.089 85 0.746 81 0.420
10 g/dL 106 90 82 85
PTf
No 104 89 0.613 85 0.007 88 0.007
Yes 15 87 66 72
DTf
No 102 89 0.293 84 0.171 86 0.450
Yes 17 83 78 92
Transfusion
No 87 90 0.202 87 0.007 88 0.075
Yes 32 83 72 83
AWNHb, average weekly nadir hemoglobin; BHb, baseline Hb; DTf, transfusion only during treatment; LN, lymph node;
LLND, laparoscopic lymph node dissection; LRRFS, locoregional recurrence free survival; MFS, metastasis free survival;
OS, overall survival; PTf, pretreatment transfusion; SCC, squamous cell carcinoma.
*p values were obtained from log-rank tests.
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of OS rates (4-years OS 83% vs. 88%, p = 0.075,
Table 4 and Fig. 5c; HR=2.821, CI 0.72 - 11.11, p =
0.138, data not presented). The transfusion group
was subdivided into the PTf and DTf, and the
survival rates of the latter were compared with
those who did not receive transfusion at all. When
the PTf and DTf subgroups were further compared
with the non-transfusion group, the 4-year MFS
and OS rates were 66% vs. 78%, and 72% vs. 92%,
respectively, while the corresponding figures were
87% and 88% for the non-transfusion group (Fig.
5b and c). Univariate analysis showed that DTf did
not significantly affect outcome, whereas PTf
resulted in a higher incidence of distant metastases
and decreased survival. Furthermore, the history
of PTf was the most significant predictor for the
development of distant metastasis and OS on
multivariable analysis (HR = 3.75, 95% CI: 1.28 -
12.15, p = 0.017; HR = 4.62, 95% CI: 1.15 - 18.54, p
= 0.031, respecstively, Table 5).
DISCUSSION
Low Hb values in cancer are generally associ-
ated with poor prognosis.
1 Therefore we examined
the impact of anemia using Hb level lower than
10 g/dL, which is more severe anemia than in
many other studies
1-4 which used Hb value lower
than 11.5- 12.5g/dL. Among the clinical parameters
included in this study, tumor histology and the
presence of metastatic pelvic LN were highly
associated with locoregional recurrence on univa-
riate analysis, whereas none of the Hb parameters
used in this study showed a significant effect.
Baseline Hb and AWNHb were both associated
with younger age in our study. This is interpreted
as due to the presence of regular menstrual
bleeding in the age below 50 years and also the
difficulty in separating periodic bleeding from
abnormal bleeding in this group of patients. In
support of this speculation, the patient of over age
50 years had more normocytic anemia, suggesting
the contribution of chronic disease to the low Hb
compared to the younger patients. Also found in
subgroup analysis was that BHb was significant
for overall survival in patient age 50 year.
Serum ferritin is known to be one of adverse pro-
gnostic marker which activates inflammatory
signal and promotes cancer cell survival.
19 The
effect of anemia could be confounded by the
ferritin or transferrin. Serum iron storage profiles
such as serum iron, total iron-binding capacity,
and ferritin level were not routinely checked in our
Table 5. Multivariable Analysis of Clinical Outcome with Variables
Factors
LRRFS MFS OS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age
(< 50 yr vs. 50 yr)
3.00
(0.75 - 11.99)
0.121
1.20
(0.39 - 3.74)
0.749
0.94
(0.22 - 3.90)
0.927
Histology
(SCC vs. Non-SCC)
5.99
(1.73 - 20.75)
0.005
1.71
(0.45 - 6.54)
0.432
1.78
(0.34 - 9.32)
0.493
Tumor size
(< 4 cm vs. 4 cm)
1.81
(0.48 - 6.89)
0.385
1.19
(0.40 - 3.50)
0.758
3.59
(0.70 - 18.34)
0.124
Pelvic LN metastasis
(Positive vs. negative)
4.12
(1.15 - 14.79)
0.030
1.61
(0.56 - 4.60)
0.375
2.12
(0.56 - 8.04)
0.267
AWNHb 1.47
(0.34 - 7.62)
1.469
1.34
(2.78 - 6.44)
0.719
1.06
(0.19 - 6.04)
0.948
PTf
(Yes vs. No)
1.61
(0.34 - 7.62)
0.550
3.75
(1.28 - 12.15)
0.017
4.62
(1.15 - 18.54)
0.031
AWNHb, average weekly nadir hemoglobin; LN, lymph node; LRRFS, locoregional recurrence free survival; MFS, metastasis
free survival; OS, overall survival; PTf, pretreatment transfusion; SCC, squamous cell carcinoma.Allogeneic Blood Transfusion Given Before Radiotherapy
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series, therefore, we could not evaluate the role of
those factors in our result. In our study, we also
found that lower AWNHb was more frequently
distributed in patients with LLND before radio-
therapy. The relationship between LLND, lower
AWNHb, and greater need for blood transfusion
in this group of patients presently observed re-
quire cautious interpretation, because the number
of patients with laparoscopy was small. Although
ABT was successful in maintaining Hb levels
above 10 g/dL during radiotherapy, Hb levels
remained lower during the course of treatment in
patients who underwent LLND compared with
those who did not. Since the median and mean Hb
values at initial presentation were similar in the
LLND and non-LLND groups, the higher overall
transfusion rate in both the LLND group may
reflect that this surgical procedure itself as well as
the preference of surgeons for ABT in patients who
will undergo surgical procedure contribute to
lowering the Hb level.
We found that patients who received ABT had
a poorer prognosis and this adverse effect was
distinctively apparent in the higher rate of distant
metastases in the subset of patients who were
given ABT before treatment started (PTf). We
speculate that this finding might suggest that ABT
negatively affected patient's outcome more seri-
ously because it was given during the phase when
the tumors were composed of large number of
viable cancer cells and were more under the
control of paracrine effect of tumor microen-
vironment and had disrupted tumor vasculature,
whereas DTf was given mostly for correction of
cisplatin-induced anemia in the later part of the
treatment course. Once definitive radiotherapy
with or without chemotherapy given and begins
to induce the tumor bed effect,
20-22 and once the
tumors starts to regress, the ABT may no longer
activate the tumor cells.
23,24 Several mechanisms,
based on pre-clinical findings, have been sug-
gested to support the adverse effect of ABT, and
the leukocyte component of donor blood is con-
sidered mostly responsible for the altered immune
function. Decreased natural killer cell activity was
observed in blood-transfused mice in an in vivo
metastasis model and also in the plasma of the
transfused patients along with the increased inter-
leukin (IL)-10 level.
14,25 In one study, higher
median number of metastases was observed when
there were higher white blood cell counts in the
blood.
15 In addition, the presence of allogeneic
leukocytes in a co-culture of murine endothelial
cells and lung carcinoma cells increased tumor cell
adhesion, suggesting that allogeneic leukocytes
influence metastatic potential by modulating
intercellular adhesion molecules.
26
However, our study has several limitations in
showing that this adverse effect was solely in-
fluenced by allogeneic blood transfusion, although
multivariable analysis revealed that history of ABT
remained the strongest parameter in predicting
distant metastases. First, our analysis was retro-
spective in nature and the implementation of
transfusion could have been affected by the pre-
ference and robustness of individual physicians in
recommending transfusion as well as by the choice
of patients. Second, more importantly, there was
a possibility that the presently observed effect of
ABT was confounded by the presence of severe
anemia because there were more patients with Hb
below 9 g/dL in patients with ABT before treat-
ment (data not shown). Hence, there is a possibility
of a multicollinearity problem remaining between
anemia and transfusion, which we could not fully
identify with the small number of our patients.
Nevertheless, our results indicate that our past
practice in the management of anemia may have
been erroneous.
The adverse effect of ABT is extremely important
in the treatment of patients with cervical cancer
because these patients are considered as a subset
of patients who already have immune defense
mechanisms attenuated. The development of inva-
sive cervical cancer is due to interaction between
HPV infection, the host immunity, and genetic
factors.
27 Treatment outcome in patients with
cervical cancer was shown to correlate with plasma
and cervical residual HPV viral load,
28,29 again
suggesting that the disruption of the local host
immune barrier could be an important factor
associated with poorer treatment outcome in this
disease. Heavy bleeding may also contribute to a
deterioration of immune function in these patients
because isolated hemorrhages, even without tissue
injury, have been shown to cause immunosuppres-
sion and higher mortality rate in mouse model.
30
Although it is not clear whether the use ofMyong Cheol Lim, et al.
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pre-storage leukocyte-depleted blood products
would prevent these adverse effects, the use of
leukocyte-free blood compound is strongly recom-
mended in situations requiring blood transfu-
sions, thus minimizing the immune modulating
effects of ABT in patients with cervical cancer.
15,31
It is of utmost importance, however, that ABT
should be saved for the patients with acute blood
loss who are considered in need of immediate
correction of anemia, or for those patients who are
chronically ill and cachexic, and therefore, tissue
hypoxia is not likely to be compensated by normal
physiologic mechanisms.
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